Health Minister Hon. Jane Philpott Announces Consultations on proposed changes to the Patented Medicines Regulations
Speaking today at the Economic Club of Canada in Ottawa, Federal Health Minister Jane Philpott announced the opening of a consultation period concerning proposed changes to the Patented Medicines Regulations that would have significant effects on the Patented Medicines Prices Review Board (PMPRB) and its activities regulating prices of patented medicines in Canada.
The proposed changes, detailed in the Health Canada report Protecting Canadians from Excessive Drug Prices Consulting on Proposed Amendments to the Patented Medicines Regulations focus on 5 key areas:
- Introducing new factors to help determine whether a price is excessive
- Amending the list of countries used for international price comparisons – US & Switzerland are removed; Australia, Belgium, Japan, Netherlands, Norway, South Korea & Spain have been added
- Reducing regulatory burden for generic drugs with a patent
- Modernizing reporting requirements for patentees
- Providing information related to third party rebates
The consultation period is open until June 28, 2017. For more information please visit the Government of Canada website here: https://www.canada.ca/en/health-canada/programs/consultation-regulations-patented-medicine.html
PDCI will be holding a webinar (for industry) on the implications of the proposed changes on drug pricing in Canada.
Date and time of the PDCI webinar to be announced shortly